Stay updated on Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.

Latest updates to the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new page revision tag (v3.6.6) appears, replacing the previous v3.6.5. This signals an update to the page's metadata rather than any changes to the study content.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision label updated to v3.6.5, replacing the previous v3.6.4. This reflects a small maintenance update to the site's revision history and does not change the study content.SummaryDifference0.0%

- Check49 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, indicating a new page version. No study details or eligibility criteria are changed by this update.SummaryDifference0.0%

- Check70 days agoChange DetectedThe page revision was updated from v3.6.2 to v3.6.3, signaling a minor update to the page template or underlying system.SummaryDifference0.0%

- Check77 days agoChange DetectedRevision metadata updated from v3.6.0 to v3.6.2, indicating a maintenance/template update to the page. No changes to study details, eligibility criteria, or results are reflected.SummaryDifference0.0%

- Check92 days agoChange DetectedThe page now signals that it is no longer seeking participants, and adds new user-help sections (How to Read a Study Record, Common Questions, How to Join a Study) with a reformatting of the Intervention/Treatment label and an updated revision stamp from v3.5.5 to v3.6.0.SummaryDifference0.4%

Stay in the know with updates to Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib and Tislelizumab Combination in Solid Tumors Clinical Trial page.